Sat01192019

Robins Global News & Noticias



  • Odds: Packers vs. Bears
    Odds: Packers vs. Bears
  • Featured Guest Post
    Featured Guest Post
  • Publicación de invitado destacado
    Publicación de invitado destacado
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Prim


Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After Cholesterol ManagementCardiovascular Death Reduced by 20%
Fatal or Nonfatal Heart Attacks Reduced by 31%
Fatal or Nonfatal Stroke Reduced by 28%
Urgent or Emergent Coronary Revascularization Reduced by 35%
Hospitalization for Unstable Angina Reduced by 32%
Number Needed to Treat for Primary Composite Endpoint: 21Patient Years of Study Support Favorable Benefit/Risk Profile in REDUCE-ITAffordably Priced Vascepa Positions Amarin with Potential to Help Millions of PatientsConference Call Scheduled for Today, Saturday, November 10, 2018 at 7:15 pm CT/8:15 pm ETCHICAGO, Nov. 10, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT™, following presentation of the late-breaking clinical trial results at the 2018 Scientific Sessions of the American Heart Association (AHA) in Chicago, Illinois.  REDUCE-IT primary results confirmed 25% relative risk reduction (RRR) for the topline primary endpoint result with multiple robust demonstrations of efficacy, including 20% reduction in cardiovascular death.Cardiovascular benefits appeared not to be influenced significantly by triglyceride (TG) levels at baseline (135 mg/dL to 499 mg/dL baseline range) or as achieved at one year, suggesting mechanisms at work with use of Vascepa that are independent of triglyceride reduction. Results were robust across multiple subgroups, including in patients with and without diabetes at baseline. REDUCE-IT study results were simultaneously published in The New England Journal of Medicine and are available at nejm.org/doi/full/10.1056/NEJMoa1812792.  REDUCE-IT was a global study of 8,179 statin-treated adults with elevated CV risk. Many patients with well-managed LDL-C remain at high risk for cardiovascular events. No therapy is currently approved to treat the residual risk in REDUCE-IT patients and no other therapy has demonstrated a 25% risk reducti...


Posted: 2018-11-10 20:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.






Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Prim | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down

Tue, 13 Nov 2018 07:49:00 GMT

Back then, the REDUCE-IT analysis showed that the use of Vascepa 4gms/day resulted in 25% relative risk reduction (RRR) as the primary endpoint of a major adverse cardiovascular event (MACE) when comp...

Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes

Mon, 05 Nov 2018 03:57:00 GMT

Only 31 percent of REWIND trial participants had established CV disease INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/ -- Trulicity ® (dulaglutide) significantly reduced major adverse cardiovascular events ( ...

Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes

Mon, 05 Nov 2018 03:53:00 GMT

INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/ -- Trulicity ® (dulaglutide) significantly reduced major adverse cardiovascular events (MACE), a composite endpoint of cardiovascular ... to demonstrate superio...

REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint

Mon, 24 Sep 2018 01:51:00 GMT

Key topline results include: Efficacy: Approximately 25% relative risk reduction, demonstrated to a high degree of statistical significance (p0.001), in the primary endpoint composite of ... which sho...

EU approves Repatha for reduction of CV risk

Tue, 22 May 2018 16:40:00 GMT

Also, the study found a statistically significant 20 percent reduction in major adverse cardiovascular events (MACE) as per the key secondary composite endpoint of time to first ... and at risk of a c...

Related Bing Web Search

Cardiovascular safety and efficacy of the PCSK9 inhibitor ...

(Thu, 10 Jan 2019 19:52:00 GMT)

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

The Evaluation of Bococizumab (PF-04950615; RN316) in ...

(Fri, 11 Jan 2019 17:35:00 GMT)

Event rate per 100 participant-years for first occurrence of composite endpoint of CV Death, non-fatal MI or non-fatal stroke (adjudicated by Adjudication Committee) was reported.

The Evaluation of Bococizumab (PF-04950615;RN316) in ...

(Mon, 14 Jan 2019 23:15:00 GMT)

Event rate per 100 participant-years for first occurrence of composite endpoint of CV death, non-fatal MI or non-fatal stroke (adjudicated by Adjudication Committee) was reported.

Cozaar - FDA prescribing information, side effects and uses

(Tue, 15 Jan 2019 14:31:00 GMT)

Figure 2: Kaplan-Meier estimates of the time to fatal/nonfatal stroke in the groups treated with Cozaar and atenolol. The Risk Reduction is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. Table 3 shows the results for the primary composite endpoint and the individual endpoints.

2017 Focused Update of the 2016 ACC Expert Consensus ...

(Mon, 14 Jan 2019 04:31:00 GMT)

In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)–cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk.

PCSK-9 and Cardiovascular Outcomes | PodBlog

(Tue, 11 Dec 2018 21:03:00 GMT)

Scientific jargon can be tedious, and so it is with this new agent Rick and I discuss on PodMed this week, a PCSK9 inhibitor called evolocumab, and long term cardiovascular outcomes, as published in NEJM. As I opine to Rick, I can hardly wait for the proprietary name as the consonants strung together just don't slide easily off the tongue, and based on the results of this study these agents ...

RXFILES TRIAL SUMMARY WWW JULY 2016; UPDATED MAY 2017 ...

(Tue, 15 Jan 2019 00:26:00 GMT)

RXFILES TRIAL SUMMARY WWW JULY 2016; UPDATED MAY 2017 – .RXFILES.CA Page 1 of 3 LEADER: Liraglutide VICTOZA CV Outcomes Trial Summary 1 Liraglutide: Cardiovascular (CV) Outcomes and Mortality in Patients with Type 2 Diabetes (T2DM) In patients with T2DM and at high risk of CV events, does liraglutide reduce CV risk compared to placebo when added to standard care?

Norvasc - FDA prescribing information, side effects and uses

(Tue, 15 Jan 2019 15:07:00 GMT)

Hypertension. Norvasc ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Cardiovascular Monitoring Equipment for Home Use: Pulse ...

(Thu, 10 Jan 2019 17:50:00 GMT)

Cardiovascular Monitoring Equipment for Home Use: Pulse, Blood Pressure, Telemonitors, and Pacemaker Monitors

What is the optimal serum potassium level in ...

(Tue, 20 Jan 2004 23:56:00 GMT)

Humans evolved ingesting a potassium-rich, sodium-poor diet, and mechanisms developed to retain sodium and excrete potassium .The sodium-rich diet of modern humans produces sodium overload and potassium depletion .Hypokalemia contributes to the pathogenesis of cardiovascular disease, and many cardiovascular disorders and drugs aggravate hypokalemia .

Related News Story Videos From Youtube

Made In India Stents Vs Foreign Stents; How Do Indian Made Stents Fare Against Foreign Ones


Related Videos On: Made In India Stents Vs Foreign Stents; How Do Indian Made Stents Fare Against Foreign Ones


Peter Block, MD, on the Vitamin D and Omega-3 Trial (VITAL)


Related Videos On: Peter Block, MD, on the Vitamin D and Omega-3 Trial (VITAL)


What is SURROGATE ENDPOINT? What does SURROGATE ENDPOINT mean? SURROGATE ENDPOINT meaning


Related Videos On: What is SURROGATE ENDPOINT? What does SURROGATE ENDPOINT mean? SURROGATE ENDPOINT meaning


DAPT--Primary Endpoint Results


Related Videos On: DAPT--Primary Endpoint Results


DRF 19: Cardiovascular Outcomes for Diabetes Drugs: Lessons Learned and Path Forward


Related Videos On: DRF 19: Cardiovascular Outcomes for Diabetes Drugs: Lessons Learned and Path Forward






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.